an interesting snipet, page-33

Captain,

You make some reasonable points.

One thing you said:

"The bottom line is the company is failing to deliver on more fronts then just FDA. This is reflected in the share price, and that is a FACT."

I beg to differ - slightly but importantly.

It is NOT an established fact that the company is failing to deliver. There is clearly a PERCEPTION of this - but until we get news of the status of those various other 'fronts', it is not correct to talk of failure. That is merely speculation.

It is true that we are short on updates - so it is perhaps true that the company is failing to deliver 'visibility'.

For many, this lack of visibility has been interpreted as failure - and that has impacted the SP.

So, will the actuality (when we finally here about it) be the same as current perceptions. In my view, no. So, for me, the current SP represents a great buying opportunity.

But I agree with the sentiment that, for those with no desire to buy more and who wish to see the real value of their investment reflected in the SP, the current situation is pretty depressing. But this will pass.